Kinase inhibitors: the road ahead
FM Ferguson, NS Gray - Nature reviews Drug discovery, 2018 - nature.com
Receptor tyrosine kinase signalling pathways have been successfully targeted to inhibit
proliferation and angiogenesis for cancer therapy. However, kinase deregulation has been …
proliferation and angiogenesis for cancer therapy. However, kinase deregulation has been …
[HTML][HTML] Current status and future directions of cancer immunotherapy
H Zhang, J Chen - Journal of cancer, 2018 - ncbi.nlm.nih.gov
In the past decades, our knowledge about the relationship between cancer and the immune
system has increased considerably. Recent years' success of cancer immunotherapy …
system has increased considerably. Recent years' success of cancer immunotherapy …
[HTML][HTML] Human immunology and immunotherapy: main achievements and challenges
J Varadé, S Magadán… - Cellular & Molecular …, 2021 - nature.com
The immune system is a fascinating world of cells, soluble factors, interacting cells, and
tissues, all of which are interconnected. The highly complex nature of the immune system …
tissues, all of which are interconnected. The highly complex nature of the immune system …
[HTML][HTML] Regulation of PD-L1: emerging routes for targeting tumor immune evasion
Y Wang, H Wang, H Yao, C Li, JY Fang… - Frontiers in …, 2018 - frontiersin.org
Immune checkpoint blockade therapies (ICBTs) targeting programmed cell death 1 (PD-1)
and its ligand programmed death ligand-1 (PD-L1/B7-H1/CD274) have exhibited …
and its ligand programmed death ligand-1 (PD-L1/B7-H1/CD274) have exhibited …
[PDF][PDF] Increased incidence of venous thromboembolism with cancer immunotherapy
Background Cancer immunotherapy is associated with several immune-related adverse
events, but the relationship between immunotherapy and venous thromboembolism has not …
events, but the relationship between immunotherapy and venous thromboembolism has not …
[HTML][HTML] Relationships between lymphocyte counts and treatment-related toxicities and clinical responses in patients with solid tumors treated with PD-1 checkpoint …
A Diehl, M Yarchoan, A Hopkins, E Jaffee… - Oncotarget, 2017 - ncbi.nlm.nih.gov
The relationships between absolute lymphocyte counts (ALC), drug-related toxicities, and
clinical responses remain unclear in cancer patients treated with PD-1 (programmed cell …
clinical responses remain unclear in cancer patients treated with PD-1 (programmed cell …
[HTML][HTML] Atlas of PD-L1 for pathologists: indications, scores, diagnostic platforms and reporting systems
Background. Innovative drugs targeting the PD1/PD-L1 axis have opened promising
scenarios in modern cancer therapy. Plenty of assays and scoring systems have been …
scenarios in modern cancer therapy. Plenty of assays and scoring systems have been …
[HTML][HTML] Role of methylation in pro-and anti-cancer immunity
A Mehdi, SA Rabbani - Cancers, 2021 - mdpi.com
Simple Summary Epigenetic mechanisms including methylation play an essential role in
regulating gene expression not only in cancer cells but also in immune cells. Although role …
regulating gene expression not only in cancer cells but also in immune cells. Although role …
Targeting regulatory T cells by curcumin: A potential for cancer immunotherapy
R Shafabakhsh, MH Pourhanifeh, HR Mirzaei… - Pharmacological …, 2019 - Elsevier
Immune system has critical roles in fighting against several diseases like cancer. Cancer
cells evolve several ways to escape from the immune system to remain alive and trigger new …
cells evolve several ways to escape from the immune system to remain alive and trigger new …
[HTML][HTML] Current landscape of therapeutic resistance in lung cancer and promising strategies to overcome resistance
Simple Summary Despite an initial response to therapy, many lung cancer patients
inevitably develop resistance to therapy leading to decreased duration of response and …
inevitably develop resistance to therapy leading to decreased duration of response and …